HeartFlow's Q1 2026 earnings call reveals strong financial performance with a 20% revenue increase, improved gross margins, and a turnaround to net income. Despite lacking specific future guidance, the positive growth in revenue and profitability, combined with increased cash flow, indicates a healthy financial trajectory. The strategic focus on R&D and market expansion further supports positive sentiment. The absence of significant negative indicators or analyst concerns in the Q&A reinforces a positive outlook for the stock price over the next two weeks.